Compare CORT & MSGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | MSGS |
|---|---|---|
| Founded | 1998 | 1879 |
| Country | United States | United States |
| Employees | 730 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.0B |
| IPO Year | 2001 | 2015 |
| Metric | CORT | MSGS |
|---|---|---|
| Price | $89.23 | $400.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $96.50 | ★ $341.29 |
| AVG Volume (30 Days) | ★ 957.9K | 310.5K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $761,407,000.00 | N/A |
| Revenue This Year | $26.08 | N/A |
| Revenue Next Year | $26.98 | $4.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $188.60 |
| 52 Week High | $91.00 | $411.73 |
| Indicator | CORT | MSGS |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 62.51 |
| Support Level | $76.41 | $357.97 |
| Resistance Level | N/A | $397.00 |
| Average True Range (ATR) | 3.76 | 12.99 |
| MACD | -0.09 | 1.07 |
| Stochastic Oscillator | 94.20 | 69.18 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.